|
Phase 1 study of KT-413, a targeted protein degrader, in adult patients with relapsed or refractory B-cell non-Hodgkin lymphoma. |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - GlaxoSmithKline; Kymera; Pfizer; Pieris Pharmaceuticals; Sanofi |
Patents, Royalties, Other Intellectual Property - Patents with AstraZeneca Plc |
|
|
|
Stock and Other Ownership Interests - Kymera |
Travel, Accommodations, Expenses - Kymera |
|
|
|
Stock and Other Ownership Interests - Alnylam; Kymera |
|
|
Employment - Forma Therapeutics; Kymera |
Stock and Other Ownership Interests - Forma Therapeutics; Kymera |
|
|
No Relationships to Disclose |
|
|
Employment - Beam Therapeutics (I); Bluebird Bio (I); Kymera; Pfizer |
Stock and Other Ownership Interests - Alnylam (I); Beam Therapeutics (I); Bluebird Bio (I); Kymera; Pfizer |
Patents, Royalties, Other Intellectual Property - Receives royalties from Yale University on an antibody used in nephrology basic research. (I) |
|
|
|
|
Stock and Other Ownership Interests - Kymera |